Skip to content
DataLookout
Menu

NCT07611019

Colchicine for the Prevention of Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Single-Center, Strategy-Stratified, Randomized, Double-Blind, Placebo-Controlled Trial

StatusEnrolling by Invitation
PhasePhase 2/3
Primary completion (estimated)

At risk: Primary completion moved at least 4 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified Show 4 more changesShow less
    • Eligibility criteria expanded, about 10 words
    • Primary and study completion pushed from Jul 2028 to Dec 2028
    • Secondary endpoints revised (7)
    • Publications: details revised at 3 of 3 entries
  2. Notable Trial status changed: Not Yet Recruiting → Enrolling by Invitation
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 2026 to Jul 6, 2026
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Percentage change in plasma colchicine concentration following initiation of cardiopulmonary bypass in the ONCAB stratum
Timeframe: From before anesthesia induction to 20-30 minutes after initiation of cardiopulmonary bypass on the day of surgery.
Incidence of new-onset atrial fibrillation or atrial flutter within 14 days after OPCAB surgery
Timeframe: From the day of surgery through postoperative day 14.

Secondary (7)

Total duration of postoperative atrial fibrillation or atrial flutter
Proportion of participants requiring cardioversion for postoperative atrial fibrillation or atrial flutter
Cumulative dose of intravenous amiodarone used for POAF treatment
Length of stay in the intensive care unit (ICU)
Total hospital length of stay
Show 2 moreShow less
30-day hospital readmission
Plasma and pericardial fluid colchicine concentrations

Arms and interventions

Colchicine GroupExperimental

Participants will receive colchicine 0.5 mg orally twice daily starting 3 days before surgery and continuing through postoperative day 7 under double-blind conditions. Randomization is stratified by surgical strategy (off-pump CABG versus on-pump CABG).

Placebo GroupPlacebo comparator

Participants will receive an identically appearing placebo tablet orally twice daily starting 3 days before surgery and continuing through postoperative day 7 under double-blind conditions. Randomization is stratified by surgical strategy (off-pump CABG versus on-pump CABG).

Drugs: Colchicine 0.5 MG oral tablet twice daily, Placebo Oral Tablet

Sites

1 site in 1 country

  • National Taiwan University HospitalTaipei, Taiwan